Badiaa El-Imad, MD
Infectious Disease · Bridgeport, WVNPI 1174778583
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $493 of the $618 with a category attached, or 79.8%. AbbVie accounts for 71.0% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $237 and has fallen 66.8% since, to $79 in 2025. Among infectious disease clinicians in WV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 30 payments — averaging $20.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$439
- Insmed, Inc.$99
- Merck$37
- Takeda Pharmaceuticals U.S.A., Inc.$16
- Paratek Pharmaceuticals, Inc.$15
- Amgen$13
What the payments were for
- Food & beverage$49380%
- Education$12520%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $439 |
| Insmed, Inc. | 1 | $99 |
| Merck | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Paratek Pharmaceuticals, Inc. | 1 | $15 |
| Amgen | 1 | $13 |
How this compares
$618 in reported general payments places this provider in the 90th percentile of 39 infectious disease providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 16 | $60,104 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 12 | $50,450 |
| DescovyEmtricitabine/Tenofov Alafenam | 17 | $35,960 |
| Daptomycin | 13 | $13,537 |
| ErtapenemErtapenem Sodium | 31 | $12,360 |
| Vancomycin Hcl | 15 | $3,464 |
| Rifampin | 14 | $1,021 |
| CeftriaxoneCeftriaxone Sodium | 12 | $1,018 |
| Methenamine Hippurate | 11 | $879 |
| Doxycycline Hyclate | 21 | $617 |
| Amoxicillin | 19 | $317 |
| Levofloxacin | 15 | $193 |
| Sodium Chloride0.9 % Sodium Chloride | 21 | $73 |
| Fluconazole | 11 | $52 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Bridgeport
- Dino DelaportasBridgeport$478K
- Jonathan StanleyBridgeport$68
- Zonaira GulBeckley$2K
- Archana VasudevanMorgantown$1K
- Leeja JosephHuntington$517
- Theresa HysellHuntington$486
- Mahmoud ShormanHuntington$482
- Rashida KhakooMorgantown$246
- Kara WillenburgHuntington$222
- Taras NebelukCharleston$187
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.